Keywords: Novo Nordisk, Levemir, NovoMix, Insulin, Research, EASD

New data demonstrate benefits of modern insulins, Levemir and NovoMix 30

Article | 05 October 2009

Print This

New data on Danish firm Novo Nordisk’s modern insulins, Levemir and NovoMix 30, announced at the 45th Annual Meeting of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in